[go: up one dir, main page]

MX2015016469A - Fragmento fc de igg4 que comprende una region bisagra modificada. - Google Patents

Fragmento fc de igg4 que comprende una region bisagra modificada.

Info

Publication number
MX2015016469A
MX2015016469A MX2015016469A MX2015016469A MX2015016469A MX 2015016469 A MX2015016469 A MX 2015016469A MX 2015016469 A MX2015016469 A MX 2015016469A MX 2015016469 A MX2015016469 A MX 2015016469A MX 2015016469 A MX2015016469 A MX 2015016469A
Authority
MX
Mexico
Prior art keywords
igg4
fragment
hinge region
modified hinge
vivo
Prior art date
Application number
MX2015016469A
Other languages
English (en)
Other versions
MX365520B (es
Inventor
Sung Youb Jung
In Young Choi
Sung Hee Park
Jong Soo Lee
Yong Ho Huh
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2015016469A publication Critical patent/MX2015016469A/es
Publication of MX365520B publication Critical patent/MX365520B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un fragmento Fc de lgG4 modificado útil como vehículo de fármacos. Cuando el fragmento Fc de lgG4 modificado de la presente invención se combina con un fármaco arbitrario, el conjugado de fármaco resultante puede reducir al mínimo las funciones efectoras de Fc de lgG4 y el intercambio de cadenas con lgG in vivo mientras se mantiene la actividad in vivo y la mejora en la duración in vivo del conjugado de fármaco.
MX2015016469A 2013-05-31 2014-05-29 Fragmento fc de igg4 que comprende una region bisagra modificada. MX365520B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130063029A KR101895634B1 (ko) 2013-05-31 2013-05-31 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
PCT/KR2014/004799 WO2014193173A1 (ko) 2013-05-31 2014-05-29 변이된 힌지 영역을 포함하는 igg4 fc 단편

Publications (2)

Publication Number Publication Date
MX2015016469A true MX2015016469A (es) 2016-03-03
MX365520B MX365520B (es) 2019-06-05

Family

ID=51989123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016469A MX365520B (es) 2013-05-31 2014-05-29 Fragmento fc de igg4 que comprende una region bisagra modificada.

Country Status (20)

Country Link
US (2) US10973881B2 (es)
EP (2) EP3006455B1 (es)
JP (2) JP6649877B2 (es)
KR (1) KR101895634B1 (es)
CN (2) CN105377877A (es)
AU (5) AU2014271504A1 (es)
CA (1) CA2913886C (es)
DK (1) DK3006455T3 (es)
ES (2) ES2685617T3 (es)
HR (1) HRP20181394T1 (es)
HU (1) HUE040540T2 (es)
LT (1) LT3006455T (es)
MX (1) MX365520B (es)
MY (1) MY178831A (es)
PH (1) PH12015502645A1 (es)
PL (1) PL3006455T3 (es)
PT (1) PT3006455T (es)
RU (1) RU2696973C2 (es)
UA (1) UA115906C2 (es)
WO (1) WO2014193173A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
JP7222710B2 (ja) * 2015-09-24 2023-02-15 ハンミ ファーマシューティカル カンパニー リミテッド 免疫グロブリン断片の特定位置を連結部位として用いたタンパク質結合体
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3549950A4 (en) * 2016-12-05 2020-08-19 Hanmi Pharm. Co., Ltd. CONJUGATE WITH MITIGATED IMMUNE RESPONSE
TW201825123A (zh) * 2016-12-19 2018-07-16 南韓商韓美藥品股份有限公司 用於腦部靶向的長效蛋白質共軛物
JP2020506932A (ja) * 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
EA202090084A1 (ru) * 2017-07-07 2020-06-19 Ханми Фарм. Ко., Лтд. Новый терапевтический ферментный слитый белок и его применение
KR20190013615A (ko) * 2017-07-28 2019-02-11 한미약품 주식회사 이두로네이트 2-설파타제 결합체
EP3689914A4 (en) * 2017-09-29 2021-08-25 Hanmi Pharm. Co., Ltd. ENHANCED PERSISTENT PROTEIN CONJUGATE
RU2689522C1 (ru) * 2018-09-11 2019-05-28 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок, состоящий из растворимого внеклеточного домена человеческого tnfr1 и константной части тяжёлой цепи человеческого igg4
CN109336981A (zh) * 2018-09-19 2019-02-15 北京伟杰信生物科技有限公司 一种重组马绒毛膜促性腺激素融合蛋白及其制备方法和其应用
US11684655B2 (en) * 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
EP4556488A3 (en) * 2019-07-18 2025-08-13 Hanmi Pharm. Co., Ltd. Novel method for preparing long-acting drug conjugate through preparation of intermediate
TWI845724B (zh) * 2019-07-19 2024-06-21 大陸商上海藥明合聯生物技術有限公司 用於偶聯的多肽複合物及其應用
WO2022086190A1 (ko) * 2020-10-20 2022-04-28 주식회사 메디스팬 플라젤린 융합 단백질 및 이의 용도
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4548936A1 (en) 2023-10-30 2025-05-07 BioNTech SE Antibody-drug conjugates having a tailor-made drug-to-antibody ratio

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
US7608429B2 (en) * 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
JP2008537874A (ja) * 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
WO2006113665A2 (en) * 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
DK1928910T3 (en) * 2005-08-16 2014-03-10 Hanmi Science Co Ltd A method for mass production of an immunoglobulin Fc region without the initiating methionine residues
KR100824505B1 (ko) * 2005-08-16 2008-04-22 한미약품 주식회사 개시 메티오닌 잔기가 제거된 면역글로불린 Ｆｃ 영역의대량 생산방법
EP1999149A4 (en) * 2006-03-28 2010-01-20 Biogen Idec Inc ANTI-IGF-1R ANTIBODIES AND USES THEREOF
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
DK2662449T3 (en) * 2007-05-30 2017-05-15 Postech Academy-Industry- Found immunoglobulin fusion proteins
EP2197911A2 (en) * 2007-09-14 2010-06-23 Amgen Inc. Homogeneous antibody populations
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
JP6147670B2 (ja) * 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2014047357A1 (en) * 2012-09-21 2014-03-27 The Regents Of The University Of California Modified fc polypeptides, fc conjugates, and methods of use thereof
KR102073748B1 (ko) * 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편

Also Published As

Publication number Publication date
JP6649877B2 (ja) 2020-02-19
ES2685617T3 (es) 2018-10-10
ES2869581T3 (es) 2021-10-25
US10973881B2 (en) 2021-04-13
JP2016521690A (ja) 2016-07-25
CN116059393A (zh) 2023-05-05
JP6983202B2 (ja) 2021-12-17
US20210060129A1 (en) 2021-03-04
PH12015502645B1 (en) 2016-03-07
MX365520B (es) 2019-06-05
PL3006455T3 (pl) 2019-01-31
PH12015502645A1 (en) 2016-03-07
AU2018220146A1 (en) 2018-09-13
KR101895634B1 (ko) 2018-09-05
US20160129129A1 (en) 2016-05-12
HUE040540T2 (hu) 2019-03-28
AU2021225249B2 (en) 2023-09-07
UA115906C2 (uk) 2018-01-10
JP2020007326A (ja) 2020-01-16
EP3006455B1 (en) 2018-07-04
PT3006455T (pt) 2018-10-11
AU2023208081A1 (en) 2023-08-17
AU2014271504A1 (en) 2016-01-21
HRP20181394T1 (hr) 2018-10-19
EP3006455A1 (en) 2016-04-13
AU2018220146B2 (en) 2020-05-07
WO2014193173A1 (ko) 2014-12-04
AU2020202581B2 (en) 2021-09-23
US11147857B2 (en) 2021-10-19
EP3006455A4 (en) 2016-11-02
RU2015153162A (ru) 2017-07-06
RU2696973C2 (ru) 2019-08-07
CA2913886C (en) 2021-02-16
EP3406627A1 (en) 2018-11-28
KR20140141358A (ko) 2014-12-10
EP3406627B1 (en) 2021-03-03
CA2913886A1 (en) 2014-12-04
LT3006455T (lt) 2018-10-10
AU2021225249A1 (en) 2021-09-30
HK1220464A1 (en) 2017-05-05
MY178831A (en) 2020-10-20
AU2020202581A1 (en) 2020-05-07
DK3006455T3 (en) 2018-10-08
CN105377877A (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
PH12015502645A1 (en) Igg4 fc fragment comprising modified hinge region
UA110103C2 (uk) Модифікований туберкульозний антиген
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2014078866A3 (en) Engineered immunoglobulins with extended in vivo half-life
EA201201357A1 (ru) Антитела к cd40
IN2015DN00694A (es)
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
BR112014030278A2 (pt) anticorpo, e, composição.
MX340090B (es) Analogos de spliceostatina.
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
EP2849797A4 (en) ACTIVE CONJUGATES, CONJUGATION PROCEDURES AND USES THEREOF
NZ629697A (en) Human anti-cd27 antibodies, methods and uses
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
ZA201405405B (en) Humanized anti-epiregulin antibody,and cancer therapeutic agent comprising said antibody as active ingredient
BR112014025299A8 (pt) anticorpo de reação cruzada dirigido contra staphylococcus aureus, preparação farmacêutica e diagnóstica compreendendo o anticorpo, métodos de anticorpo de reação cruzada contra staphylococcus aureus
ZA201504538B (en) Anti-lamp1 antibodies and antibody drug conjugates ,and uses thereof
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
SG11201506358PA (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
EP3747907A3 (en) Methods and compositions for treating and preventing disease associated with avb8 integrin
EP3042956A4 (en) Antibody which specifically reacts with human integrin a6b4
AU2013253581A8 (en) Anti-human CD69 antibody, and use thereof for medical purposes
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями

Legal Events

Date Code Title Description
FG Grant or registration